AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

NASDAQ:AKBA • US00972D1054

1.26 USD
-0.05 (-3.82%)
At close: Mar 2, 2026
1.2498 USD
-0.01 (-0.81%)
Pre-Market: 3/3/2026, 8:38:35 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AKBA. AKBA was compared to 520 industry peers in the Biotechnology industry. While AKBA is still in line with the averages on profitability rating, there are concerns on its financial health. AKBA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • AKBA had negative earnings in the past year.
  • In the past year AKBA had a positive cash flow from operations.
  • In the past 5 years AKBA always reported negative net income.
  • In the past 5 years AKBA reported 4 times negative operating cash flow.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of AKBA (-1.42%) is better than 87.31% of its industry peers.
  • The Return On Equity of AKBA (-16.39%) is better than 85.19% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 9.54%, AKBA belongs to the top of the industry, outperforming 93.85% of the companies in the same industry.
Industry RankSector Rank
ROA -1.42%
ROE -16.39%
ROIC 9.54%
ROA(3y)-18.12%
ROA(5y)-26.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • With an excellent Operating Margin value of 10.92%, AKBA belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
  • With an excellent Gross Margin value of 82.83%, AKBA belongs to the best of the industry, outperforming 86.35% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AKBA has grown nicely.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 82.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.51%
GM growth 5Y8.51%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AKBA is still creating some value.
  • Compared to 1 year ago, AKBA has more shares outstanding
  • Compared to 5 years ago, AKBA has more shares outstanding
  • AKBA has a better debt/assets ratio than last year.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -4.53, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
  • AKBA has a worse Altman-Z score (-4.53) than 61.35% of its industry peers.
  • The Debt to FCF ratio of AKBA is 3.23, which is a good value as it means it would take AKBA, 3.23 years of fcf income to pay off all of its debts.
  • AKBA has a better Debt to FCF ratio (3.23) than 92.50% of its industry peers.
  • AKBA has a Debt/Equity ratio of 5.40. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 5.40, AKBA is not doing good in the industry: 80.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 5.4
Debt/FCF 3.23
Altman-Z -4.53
ROIC/WACC1.29
WACC7.41%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.55 indicates that AKBA should not have too much problems paying its short term obligations.
  • AKBA's Current ratio of 1.55 is on the low side compared to the rest of the industry. AKBA is outperformed by 80.58% of its industry peers.
  • AKBA has a Quick Ratio of 1.46. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
  • AKBA has a worse Quick ratio (1.46) than 80.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.46
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 93.94% over the past year.
  • AKBA shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.46%.
  • AKBA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.32% yearly.
EPS 1Y (TTM)93.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)47.46%
Revenue growth 3Y-6.88%
Revenue growth 5Y-4.32%
Sales Q2Q%23.92%

3.2 Future

  • The Earnings Per Share is expected to grow by 62.06% on average over the next years. This is a very strong growth
  • AKBA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.09% yearly.
EPS Next Y-295.25%
EPS Next 2Y-105.12%
EPS Next 3Y98.15%
EPS Next 5Y62.06%
Revenue Next Year2.87%
Revenue Next 2Y-3.54%
Revenue Next 3Y3.25%
Revenue Next 5Y13.09%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKBA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 95.58% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, AKBA is valued cheaper than 99.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.64
EV/EBITDA 12.79
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AKBA's earnings are expected to grow with 98.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.12%
EPS Next 3Y98.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AKBA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (3/2/2026, 8:01:57 PM)

Premarket: 1.2498 -0.01 (-0.81%)

1.26

-0.05 (-3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners47.63%
Inst Owner Change-9.77%
Ins Owners3.57%
Ins Owner Change7.33%
Market Cap337.53M
Revenue(TTM)236.20M
Net Income(TTM)-5.34M
Analysts87.27
Price Target4.69 (272.22%)
Short Float %12.41%
Short Ratio9.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.96%
Min EPS beat(2)-96.08%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)67.32%
Min EPS beat(4)-96.08%
Max EPS beat(4)165.36%
EPS beat(8)4
Avg EPS beat(8)25.41%
EPS beat(12)7
Avg EPS beat(12)15.35%
EPS beat(16)9
Avg EPS beat(16)20.81%
Revenue beat(2)1
Avg Revenue beat(2)10.74%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)22.56%
Revenue beat(4)3
Avg Revenue beat(4)19.1%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)29.66%
Revenue beat(8)4
Avg Revenue beat(8)4.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.03%
Revenue beat(16)8
Avg Revenue beat(16)12.53%
PT rev (1m)-14.81%
PT rev (3m)-14.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-142.86%
EPS NY rev (1m)0%
EPS NY rev (3m)1860%
Revenue NQ rev (1m)-13.89%
Revenue NQ rev (3m)-13.89%
Revenue NY rev (1m)-3.25%
Revenue NY rev (3m)-3.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.43
P/FCF 5.64
P/OCF 4.96
P/B 10.35
P/tB N/A
EV/EBITDA 12.79
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.22
FCFY17.74%
OCF(TTM)0.25
OCFY20.14%
SpS0.88
BVpS0.12
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.42%
ROE -16.39%
ROCE 12.08%
ROIC 9.54%
ROICexc 70.81%
ROICexgc N/A
OM 10.92%
PM (TTM) N/A
GM 82.83%
FCFM 25.36%
ROA(3y)-18.12%
ROA(5y)-26.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.51%
GM growth 5Y8.51%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 5.4
Debt/FCF 3.23
Debt/EBITDA 6.51
Cap/Depr 638.14%
Cap/Sales 3.43%
Interest Coverage 4.24
Cash Conversion 251.19%
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.46
Altman-Z -4.53
F-Score5
WACC7.41%
ROIC/WACC1.29
Cap/Depr(3y)212.74%
Cap/Depr(5y)127.74%
Cap/Sales(3y)1.15%
Cap/Sales(5y)0.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-295.25%
EPS Next 2Y-105.12%
EPS Next 3Y98.15%
EPS Next 5Y62.06%
Revenue 1Y (TTM)47.46%
Revenue growth 3Y-6.88%
Revenue growth 5Y-4.32%
Sales Q2Q%23.92%
Revenue Next Year2.87%
Revenue Next 2Y-3.54%
Revenue Next 3Y3.25%
Revenue Next 5Y13.09%
EBIT growth 1Y155.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y247.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y267.23%
OCF growth 3YN/A
OCF growth 5YN/A

AKEBIA THERAPEUTICS INC / AKBA FAQ

What is the fundamental rating for AKBA stock?

ChartMill assigns a fundamental rating of 4 / 10 to AKBA.


What is the valuation status for AKBA stock?

ChartMill assigns a valuation rating of 6 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.


How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?

AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 5 / 10.


What is the financial health of AKEBIA THERAPEUTICS INC (AKBA) stock?

The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 3 / 10.